Tempus AI, Inc. (TEM) Down 7.4% — Should I Secure What's Left?
Key Points
Tempus AI, Inc. (TEM) retreated sharply on the session, falling 7.39% and shedding $4.28 from the prior close to settle at $53.67. Shares remained under pressure throughout the day, marking a clear retreat after recent efforts to find a floor. At this level, TEM trades closer to the lower end of its annual range than the upper, a stark reminder of how much ground has been lost since last year's highs.
Trading activity carried a distinctly bearish tone. Volume reached 6,133,256 shares, running above the 90-day average of 5,314,565—a surge in turnover that frequently accompanies intensified selling pressure. Even following the decline, TEM remains well above its 52-week low of $36.22, yet the more telling reference point for many investors is the prior peak: the stock now sits roughly 48.5% below its 52-week high of $104.32, reached on 10/09/2025. That wide gap speaks to the persistence of the longer-term downtrend, even as short-term volatility continues to dominate price action.
Within the broader Health Care sector on the NASDAQ, TEM's decline was a standout, even compared to laggards like Zoetis (ZTS), Natera (NTRA), and BioNTech SE (BNTX). For now, the stock's price action tells the central story: a high-volume selloff that leaves shares weakened and facing stiff headwinds in the middle-to-lower portion of their 52-week range.
Why Tempus AI, Inc. Price is Moving Lower
Tempus AI's latest move reflects a classic "good news versus a higher bar" dynamic. The company's launch of its Pan-Cancer HRD-RNA algorithm and encouraging preliminary Q4/FY 2025 commentary have provided some near-term support, but the broader tone remains cautious as investors debate whether recent momentum can justify an already demanding valuation. With the full Q4 earnings report due after the close on Feb. 24, additional pressure came from risk-off positioning ahead of a binary catalyst—particularly given the stock's sharp recent swings and an 18.54% monthly pullback amid sector-wide headwinds across Health Care and biotechnology.
Fundamentally, Tempus is still asking the market to look past profitability concerns. Revenue is growing at a brisk pace—latest quarterly revenue climbed to $334.21 million from $314.64 million, up 6.2% quarter over quarter, with annual revenue growth running at 84.72%—yet the business continues to operate at a loss, carrying a -18.44% profit margin and EPS of -$1.26. That combination tends to cap the upside even when contracts and bookings appear strong, as investors increasingly demand visible operating leverage before rewarding growth-stage names.
Expectations also appear stretched. Bullish analyst price targets and an enthusiastic narrative around AI-driven diagnostics can amplify the downside when guidance, margins, or the "path to profitability" fails to progress quickly enough. In a Health Care sector, sentiment can reverse sharply, and Tempus' premium story is especially vulnerable to any sign that growth is decelerating or costs are proving stubbornly resistant to improvement.
What is the Tempus AI, Inc. Rating - Should I Sell?
Weiss Ratings assigns TEM a D rating, with a current recommendation of Sell. Tempus AI was downgraded on 9/10/2024, and the rating framework continues to flag an unfavorable risk/reward setup even during periods of headline revenue growth.
A central issue is that a strong Good Growth Index has not translated into meaningful shareholder returns. Revenue growth of 84.72% is eye-catching, yet profitability remains elusive, with a -18.44% profit margin. That disconnect helps explain the negative forward P/E of -45.95: investors are still pricing a business where earnings power has yet to be established, leaving the stock acutely exposed if expectations soften or the cost of capital rises.
The sub-index breakdown further illustrates why growth alone hasn't been sufficient to move the overall grade higher. A Very Weak Efficiency Index points to poor returns on capital and limited operating leverage, while a Weak Total Return Index signals that the market has not been compensating holders for the risk they are taking. A Weak Volatility Index raises the bar further for prospective buyers, as wider swings can transform modest disappointments into outsized drawdowns.
Within Health Care sector, TEM sits in the same low-rated tier as Zoetis Inc. (ZTS, D+) and Natera, Inc. (NTRA, D-), and in close company with BioNTech SE (BNTX, D-). TEM does benefit from an Excellent Solvency Index, yet balance-sheet strength alone has not been enough to offset weak efficiency and poor risk-adjusted returns—the combination that keeps the overall Weiss Rating firmly in negative territory.
About Tempus AI, Inc.
Tempus AI, Inc. (TEM) is a U.S.-based healthcare technology company specializing in data-driven diagnostics and clinical decision support within the Pharmaceuticals, Biotechnology and Life Sciences industry. The company's flagship offering is the Tempus platform, built as a closed-loop system that connects a clinician's desktop to laboratory diagnostic capabilities, an analytics layer, and a rich repository of multimodal data. The primary clinical front end is Hub, an end-to-end application through which physicians and other healthcare providers order and manage next-generation sequencing (NGS) tests within Tempus' diagnostics product line.
The company's portfolio spans software, testing services, and data licensing. Lens serves life sciences customers and precision research workflows, while the diagnostics business encompasses NGS diagnostics, PCR profiling, and a broad suite of anatomic and molecular pathology tests. Tempus operates multiple assays for large-panel solid tumor and hematologic testing; its core clinical assays, xT and xR, combine large-panel DNA and RNA full-transcriptome analysis and can report incidental germline findings using a normal blood or saliva sample. Beyond oncology, Tempus offers genetic tests for inherited conditions and the nP assay for pharmacogenomic testing in psychiatric care, covering depression, generalized anxiety disorder, and bipolar disorder.
Tempus further monetizes de-identified datasets through its Insights offering, provides tumor-derived biological modeling via Organoids, and enables clinical trial matching through Trials. The company also markets AI-powered tools such as Next and Algos, and collaborates with strategic partners including AstraZeneca, Pathos AI, GlaxoSmithKline, and Recursion Pharmaceuticals. Founded in 2015 and headquartered in Chicago, the company rebranded from Tempus Labs, Inc. to Tempus AI, Inc. in January 2023.
Investor Outlook
Carrying a Weiss Rating of D (Sell), Tempus AI, Inc. (TEM) heads into the next phase with a risk/reward profile that warrants caution, even if near-term sentiment finds some footing. Investors would do well to monitor whether the stock can hold key support levels and reclaim prior resistance, while keeping a close eye on broader Health Care risk appetite—weak follow-through in either area could amplify downside volatility meaningfully. See full rankings of all D-rated Health Care stocks inside the Weiss Stock Screener.
--